Nature Medicine | Spoonful of Medicine

Cancer concerns emerge about experimental diabetes drug ahead of FDA evaluation

Ahead of a US Food and Drug Administration advisory committee meeting next month to evaluate the experimental diabetes drug dapagliflozin, its developers, Bristol-Myers Squibb and AstraZeneca, released positive two-year trial data over the weekend showing that the medication lowered blood sugar levels more than other diabetes drugs. But people on dapagliflozin also had higher rates of certain cancers and infections, which could factor into regulatory decisions at the 19 July panel meeting. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.